VCVictoria Hope Coleman-Cowger

Victoria Hope Coleman-Cowger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Victoria Hope Coleman-Cowger has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cure Sickle Cell Initiative recommendations on common data elements for sickle cell disease gene therapy trials

    by Sophie Lanzkron, Victoria H. Coleman-Cowger, Alexis A. Thompson, C. Patrick Carroll, Traci Clemons, Michael R DeBaun, Julie Washko Kanter, Punam Malik, Deepa G Manwani, Francis John Pierciey, et al.

    The Cure Sickle Cell Initiative (CureSCi), created by the National Heart, Lung, and Blood Institute, has developed data standards to increase interoperability and meta-analysis of studies specifically investigating gene therapy for sickle cell disease (SCD). The aims of the CureSCi Common Data Elements (CDE) initiative are to facilitate the development of safe, effective, and accessible gene therapies. Five working groups (WGs) comprising people living with SCD, stakeholders, clinicians, and researchers reviewed current definitions used for SCD clinical studies, including those from the American Society of Hematology, US Food and Drug Administration, PhenX catalog of consensus measures for phenotypes and exposures, and others. The WGs met over 1.5 years to develop a comprehensive list of defined data points and variables recommended for any gene therapy clinical trial that incorporated feedback from a 60-day public review period. The SCD CDEs are publicly available on the CureSCi (curesickle.org/datatools-overview) and the National Institutes of Health (NIH) Repository (cde.nlm.nih.gov/home) websites. In addition to data elements, there are 42 instrument recommendations, including those from the Patient-Reported Outcomes Measurement Information System and NIH Toolbox, and 49 template case report forms for various stages of a study (eg, demographic, disease history, treatment, and outcome). CureSCi data element recommendations build upon current consensus data elements and facilitate the start-up of multicenter clinical research efforts. This standardized set of clinical research recommendations will increase the ability to compare outcomes across studies, increase data quality, and help educate new clinical investigators in the field of SCD gene therapy research.


  • Open Access

    Mental health challenges associated with sickle cell disease and strategies to address them: Reflections from a community input panel

    by Adedotun Adeyokunnu, Heather Avant, Steven Hardy, Carolyn Rowley, Carley Cole-Cavins, Titilope Fasipe, LaTonya Kittles, Victoria H. Coleman-Cowger


  • Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease

    by Mary Eapen, Ruta Brazauskas, David A. Williams, Mark C. Walters, Andrew St Martin, Benjamin L. Jacobs, Joseph H. Antin, Kira Bona, Sonali Chaudhury, Victoria H. Coleman-Cowger, et al.

    PURPOSE: To report the incidence and risk factors for secondary neoplasm after transplantation for sickle cell disease. METHODS: Included are 1,096 transplants for sickle cell disease between 1991 and 2016. There were 22 secondary neoplasms. Types included leukemia/myelodysplastic syndrome (MDS; n = 15) and solid tumor (n = 7). Fine-Gray regression models examined for risk factors for leukemia/MDS and any secondary neoplasm. RESULTS: The 10-year incidence of leukemia/MDS was 1.7% (95% CI, 0.90 to 2.9) and of any secondary neoplasm was 2.4% (95% CI, 1.4 to 3.8). After adjusting for other risk factors, risks for leukemia/MDS (hazard ratio, 22.69; 95% CI, 4.34 to 118.66; P = .0002) or any secondary neoplasm (hazard ratio, 7.78; 95% CI, 2.20 to 27.53; P = .0015) were higher with low-intensity (nonmyeloablative) regimens compared with more intense regimens. All low-intensity regimens included total-body irradiation (TBI 300 or 400 cGy with alemtuzumab, TBI 300 or 400 cGy with cyclophosphamide, TBI 200, 300, or 400 cGy with cyclophosphamide and fludarabine, or TBI 200 cGy with fludarabine). None of the patients receiving myeloablative and only 23% of those receiving reduced-intensity regimens received TBI. CONCLUSION: Low-intensity regimens rely on tolerance induction and establishment of mixed-donor chimerism. Persistence of host cells exposed to low-dose radiation triggering myeloid malignancy is one plausible etiology. Pre-existing myeloid mutations and prior inflammation may also contribute but could not be studied using our data source. Choosing conditioning regimens likely to result in full-donor chimerism may in part mitigate the higher risk for leukemia/MDS.


  • Open Access

    Birth Outcomes Associated With E-Cigarette and Non–E-Cigarette Tobacco Product Use During Pregnancy: An Examination of PATH Data Waves 1–5

    by Amy M Cohn, Hoda Elmasry, Robert C Wild, Amanda L Johnson, Haneen Abudayyeh, Allison Kurti, Victoria H Coleman-Cowger

    To examine associations of prenatal e-cigarette use to pregnancy and birth outcomes. Currently pregnant women (n = 1 037) from Waves 1 through 4 of the Population Assessment of Tobacco and Health Study who had pregnancy or live birth outcome data in a subsequent wave (Waves 2–5; 2013 to 2019). Weighted bivariate and multivariable models\ examined associations between past 30-day tobacco use assessed during pregnancy (any past 30-day e-cigarette use, any past 30-day non–e-cigarette tobacco use, or no past 30-day tobacco use) with adverse pregnancy (miscarriage, abortion, ectopic or tubal pregnancy, stillbirth) and birth outcomes (preterm birth, low birth weight, birth defect, placenta previa, placental abruption, pre-eclampsia) reported in the subsequent wave. Approximately 1% of pregnant women reported past 30-day exclusive e-cigarette use and 3.2% used e-cigarettes and one other tobacco product. Compared to no tobacco use, past 30-day e-cigarette use (exclusive or use with another tobacco product) during pregnancy was not associated with increased odds of an adverse pregnancy or birth outcome in bivariate or multivariable models. Past 30-day non–e-cigarette tobacco use was associated with increased odds of an adverse pregnancy outcome in multivariable models, but not an adverse live birth outcome. Compared to past 30-day cigarette use, past 30-day e-cigarette use during pregnancy was not associated with lowered odds of a birth or pregnancy outcome. E-cigarette use during pregnancy is rare. Understanding the positive and negative impacts of pre–natal e-cigarette use on women’s health may guide public health messaging campaigns. Results showed that past 30-day e-cigarette use during pregnancy was low, with cigarette smoking remaining the most prevalent form of tobacco use during pregnancy. Current e-cigarette use during pregnancy used either exclusively or with another tobacco product, was not associated with increased risk of an adverse pregnancy, or birth outcome. A small sample size of e-cigarette users and limited information on quantity and frequency of e-cigarette use before and during pregnancy may limit conclusions. Healthcare providers may use this information when discussing the harms and consequences associated with e-cigarette and tobacco use during pregnancy.


  • Patient Perceptions of Three Substance Use Screening Tools for Use During Pregnancy

    by Kathleen E. Trocin, Emmanuel A. Oga, Caroline Mulatya, Katrina S. Mark, Victoria H. Coleman-Cowger

    Objectives The purpose of this study was to understand pregnant women’s perceptions of three validated substance use screening tools and identify a preferred tool for use during pregnancy. The three screening tools studied included the 4P’s Plus, the NIDA Quick Screen/ NIDA-Modified Alcohol, Smoking and Substance Involvement Screening Test, and the Substance Use Risk Profile-Pregnancy Scale. Methods A total of 493 cognitive interviews were completed with a diverse sample of pregnant women presenting to two obstetrics practices in Baltimore, MD from January 2017 to January 2018. This study served as a qualitative companion to a larger study comparing the accuracy and acceptability of substance use screening tools in prenatal care. After completing each screening tool, participants were asked their perceptions of the tool and to choose their preferred tool. Interviews were recorded, transcribed verbatim, coded, and analyzed using NVivo software. Results The plurality of participants (43.4%) reported they preferred the 4P’s Plus. Fewer participants preferred the NIDA Quick Screen (32.5%) and the SURP-P (24.1%). Participants felt that the 4P’s Plus was both comprehensive and concise. While many participants felt that disclosure of substance use would vary by individual, participants also suggested that when screening is confidential, includes questions about a patient’s background, and administered by a non-judgmental provider, pregnant people may be more likely to answer honestly. Conclusions for Practice The 4P’s Plus is a promising and acceptable substance use screening tool for use in prenatal care. Clinicians can use several methods to increase acceptability of substance use screening and encourage disclosure of prenatal substance use.


  • Prenatal Practice Staff Perceptions of Three Substance Use Screening Tools for Pregnant Women

    by Kathleen E. Trocin, Nicole I. Weinstein, Emmanuel A. Oga, Katrina S. Mark, Victoria H. Coleman-Cowger

    Objective: There is a need to identify an acceptable and comprehensive substance use screening tool for pregnant women in the United States. This qualitative study sought to better understand prenatal practice staff perceptions of three existing substance use screening tools for use among pregnant women in an outpatient practice setting. Methods: Eight focus groups with 40 total participants were conducted with clinical and administrative staff of 2 diverse Maryland prenatal practices to determine the acceptability and usability of 3 substance use screening tools (4P's Plus, NIDA-Modified Alcohol, Smoking and Substance Involvement Screening Test, and the Substance Use Risk Profile-Pregnancy scale). The focus groups were digitally recorded, transcribed, coded, and analyzed using thematic analysis. Results: Participant perceptions of screening tools were dependent upon screening tool length, tone, comprehensiveness, subjectivity, time frame of questions, and scoring and clinician instructions. Most participants preferred the 4P's Plus screening tool because it is brief, comprehensive, easy for the patient to understand, and excludes judgmental language and subjective questions. Conclusions: These results provide valuable insight into the specific needs and preferences of prenatal practice staff as it relates to prenatal substance use screening and provides evidence that the 4P's Plus may be a preferred screening tool for standardized use in prenatal care.


  • Impact of electronic nicotine delivery systems and other respondent characteristics on tobacco use transitions among a U.S. national sample of women of reproductive age

    by Allison N. Kurti, Janice Y. Bunn, Katherine Tang, Tyler Nighbor, Diann E. Gaalema, Victoria Coleman-Cowger, Sulamunn R.M. Coleman, Stephen T. Higgins